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Objective: To evaluate the outcome and to confirm the validity of cochlear implantation 2 
for syndromic deafness in patients with mitochondrial disease. 3 
Study design: Retrospective case review 4 
Setting: Tertiary referral center 5 
Patients: We reviewed medical charts of 367 cochlear implantation cases at Kyoto 6 
University Hospital between 1987 and 2012. We identified 5 patients with syndromic 7 
mitochondrial disease who underwent cochlear implantation surgery. The mean age of 8 
the patients (4 women and 1 man) when they underwent surgeries was 44.4 years 9 
(range 30–64years, median 41 years). 10 
Interventions: Therapeutic and rehabilitative 11 
Main outcome measure: In 4 out of 5 patients, speech perception performance was 12 
measured using Japanese vowels, consonant-vowel syllables, and short sentences. 13 
Results: Only 1.4% (5/367) of cochlear implantation cases at Kyoto University Hospital 14 
underwent cochlear implantation surgery due to syndromic mitochondrial diseases. 15 
Four of those patients showed significantly improved speech perception outcomes, and 16 
the beneficial effects of the intervention continued long after surgery. One patient could 17 
not perform speech perception test presumably due to poor cognitive function. 18 
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Conclusions: Mitochondrial disease patients who underwent cochlear implantation 19 
surgery sustained gains in hearing performance even long after surgery. A single 20 
patient showed poor postoperative speech perception associated with cognitive problems. 21 
Cochlear implantation for mitochondrial disease patients appears to be a viable 22 
treatment option in the absence of significant cognitive impairment. 23 
 24 
INTRODUCTION 25 
Mitochondrial diseases are caused by mutation of either mitochondrial DNA or of 26 
nuclear DNA that encodes genes related to mitochondrial function. Mitochondrial 27 
diseases result in dysfunction of the respiratory chains that are important for producing 28 
adenocine triphosphate (ATP) in eukaryotic cells (1). More than half of the known 29 
mitochondrial diseases cause various levels of sensorineural hearing loss (SNHL) (2) 30 
that is classified into either non-syndromic or syndromic hearing loss. Mitochondrial 31 
diseases with syndromic hearing loss include mitochondrial encephalomyopathy, lactic 32 
acidosis, and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibers 33 
(MERRF), maternally inherited diabetes with deafness (MIDD), Kearns-Sayre 34 
syndrome (KSS), and chronic progressive external ophthalmoplegia (CPEO). Some 35 
mitochondrial diseases can cause severe to profound SNHL, necessitating the use of 36 
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cochlear implants for syndromic (3-15), as well as non-syndromic (16-18), mitochondrial 37 
deafness. 38 
Most previous case reports suggested that cochlear implantation (CI) has favorable 39 
effects in both types of mitochondrial diseases, based solely on the outcome at 1 time 40 
point or within at most 2 years after surgery. Although these results are supported by 41 
the fact that the SNHL in mitochondrial diseases is attributed to cochlear dysfunction 42 
(19,20), mitochondrial diseases with syndromic deafness can affect the central nervous 43 
system, including the central auditory pathway, or cause psychomotor regression after 44 
CI (1). Thus, the beneficial effects of cochlear implants may further change even after 45 
determination of the initial treatment outcome or within several years after surgery, 46 
since continued normal function of the central auditory pathway and stable 47 
psychological conditions are necessary for successful CI. In this study, we present the 48 
outcomes of CI on a longitudinal basis at several time points in cases of syndromic 49 
mitochondrial deafness that presented at Kyoto University Hospital and discuss the 50 
validity to perform CI for syndromic mitochondrial deafness.  51 
 52 





This study was approved by Kyoto University Graduate School and Faculty of Medicine, 56 
Ethics Committee (E2359). Medical records of 367 patients who underwent CI at Kyoto 57 
University Hospital between 1987 and 2012 were reviewed. Among these, 5 patients 58 
were diagnosed with MELAS (3 patients), MIDD (1 patient), and unclassified (1 patient) 59 
mitochondrial disease in the Department of Neurology at Kyoto University Hospital. 60 
 61 
Data collection 62 
Medical records of 5 patients who underwent CI surgery were reviewed and the 63 
following information was extracted: age, sex, perioperative complications, and 64 
postoperative speech perception performance at several time points. 65 
 66 
Diagnosis of mitochondrial diseases 67 
Mitochondrial diseases were diagnosed by neurologists at Kyoto University Hospital 68 
based on genetic tests, muscle biopsies, MRI imaging of the brain, and clinical 69 
symptoms—seizures, stroke-like symptoms, recurrent headache, dementia, ataxia, 70 





Postoperative speech perception performance test 74 
Vowels, consonant-vowel (CV) syllables, and short sentences were phonated by a male 75 
professional announcer and digitized at a sampling rate of 44.1 kHz. These speech 76 
samples were presented via speakers at 70 dB SPL using a PowerMac PM-7300/166 77 
computer (Apple Inc., Cupertino, California, USA) in random order; the percentage of 78 
correct answers was recorded. In the vowel perception test, 5 Japanese vowels were 79 
presented to patients. In the CV syllable perception test, 13 CV syllables—composed of 80 
13 Japanese consonants and the vowel /a/— were presented to patients. In the phrase 81 
perception test, 10 short Japanese sentences were arranged to contain 40 different 82 
phrases. The vowel and CV syllable perception test used closed sets and the phrase 83 
perception test used an open set. These tests were administered at least 6 months after 84 
implantation. Unpaired t-tests were performed for the statistical analysis and p-values 85 




Patient characteristics (Table) 90 
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Only 1.4% (5/367) of CI cases at Kyoto University Hospital underwent CI due to 91 
mitochondrial diseases. The patients—1 male and 4 females— ranged from 30 to 64 92 
years in age. Four of the patients had m.3243A>G mutation. Three patients were 93 
diagnosed with MELAS and one patient was diagnosed with MIDD. One patient (case 4) 94 
was not diagnosed with a specific mitochondrial disease because he presented with an 95 
atypical set of symptoms (deafness, ataxia, mild cognitive deficits, and paroxysmal 96 
supraventricular tachycardia). However, he was diagnosed with a general 97 
mitochondrial disease because he showed the m.3243A>G mutation and ragged-red 98 
fibers were observed in his muscle biopsy specimens. Another patient (case 3) refused to 99 
undergo a genetic test and a muscle biopsy test. However, she was clinically diagnosed 100 
with MELAS due to typical symptoms (stroke–like episodes, seizures, hemiplegia, 101 
cognitive deficits, ataxia, short stature, and deafness) and typical MRI imaging findings 102 
(basal ganglia calcification, cerebellar atrophy, and chronic infarcts involving multiple 103 
vascular territories). Patients in cases 1, 2, and 3 died 12, 4, and 2 years after CI surgery, 104 
respectively. 105 
 106 
Surgical findings 107 
We did not find any inner ear anomalies and smooth and complete electrode insertion 108 
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was achieved in all patients. Electrically evoked compound action potential (ECAP) was 109 
detected in 3 cases. The implants used in the other 2 cases (cases 1 and 3) were 110 
incompatible with ECAP measurements. 111 
Although susceptibility to malignant hyperthermia in patients with mitochondrial 112 
diseases has been reported (21), none of the patients in our series showed malignant 113 
hyperthermia. While most inhalation anesthetics and propofol can suppress complexes I 114 
and II of mitochondrial respiratory chains (22), none of our patients suffered from any 115 
problems. 116 
 117 
Postoperative speech perception performance test 118 
Four out of the five patients showed good performance in the speech perception 119 
performance test after CI. The average performance of these 4 patients (92.5% for 120 
vowels, 45.0% for CV syllables, and 78% for sentences, Figure 1) was comparable to that 121 
of the other CI patients with post-lingual deafness at Kyoto University Hospital (23) 122 
(85.2% for vowels, 41.1% for CV syllables, and 80.1% for sentences, Figure 1). The mean 123 
speech perception results were not significantly different between those of a 124 
mitochondrial disease patients group and those of a control group with p values of 0.23 125 
for vowels, 0.71 for CV syllables, and 0.90 for sentences. This good performance 126 
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persisted for at least 8 and 3 years after surgery in case 1 and case 2, respectively 127 
(Figures 2 and 3). Case 4 and case 5, in which the tests were conducted only once, also 128 
showed good results in the speech perception performance test 2 years and 1.5 years 129 
after surgery, respectively (Figure 4). In case 3 the patient could not participate in the 130 
speech perception performance test even 2 years after CI surgery presumably due to the 131 
poor cognitive function. This patient’s average threshold in the sound field pure-tone 132 
audiometry was 30–45 dB hearing level from 250–4000 Hz at 1 year after CI surgery. 133 
 134 
Discussion 135 
Possible causes of SNHL by mitochondrial diseases with syndromic hearing loss are 136 
cochlear dysfunction and retrocochlear impairment. Several studies suggested that 137 
cochlear dysfunction was the more probable cause of SNHL in mitochondrial diseases 138 
with syndromic hearing loss (19,20). However, other reports suggested the involvement 139 
of retrocochlear impairment based on the increased latency in auditory brain stem 140 
response (ABR) (24,25). Favorable outcomes of CI (3-15), including the preserved 141 
retrocochlear function shown by an electrically induced middle latency response (MLR) 142 
(5,10,12), supported the cochlear origin of SNHL in mitochondrial diseases theory. Our 143 
results were consistent with these previous reports (Figure 2–4). However, most of the 144 
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previous reports evaluated outcomes only once within 2 years after surgeries. 145 
Since impairment of retrocochlear function may occur many years after CI surgeries 146 
and may cause deterioration of CI outcomes, repeated evaluations over a longer period 147 
are imperative. In this study, we performed the postoperative speech perception 148 
performance test on 2 patients (cases 1 and 2) several times over 8 and 3 years, 149 
respectively. These results showed the preservation of retrocochlear function in both 150 
MELAS and MIDD patients over extended periods after their CI surgeries. While 5 151 
years of follow-up of the CI outcome has been reported for MIDD patients (8), the 152 
audiological evaluation in our study showed that even in MELAS, which is considered 153 
more severe mitochondrial disease than MIDD (12), the retrocochlear function was 154 
preserved over an extended period of time. 155 
In addition to the dysfunction of central auditory pathways, cognitive problems should 156 
be considered when deciding the indications for CI especially in severe mitochondrial 157 
diseases such as MELAS. The cognitive deficit sometimes causes the limited usage of a 158 
cochlear implant. The patient in case 3 had a strong desire to recover her hearing ability 159 
prior to her CI surgery. However, she could not recognize the importance of using her 160 
implant for the establishment of speech perception; she used her implant only several 161 
hours per day. As a result, she could not undergo the speech perception performance test 162 
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2 year after CI surgery. This was despite her sound field pure-tone audiometry result 163 
being comparable to that for the other CI users. 164 
Among the 5 patients, 3 died 12, 4, and 2 years after their CI surgeries. The poor 165 
prognosis of MELAS (26) raises the problem of cost-effectiveness of CI for syndromic 166 
deafness due to mitochondrial diseases. Nevertheless, the long-term preferable 167 
outcomes of CI in mitochondrial diseases shown in this study, and the possibility of 168 
other severe symptoms caused by mitochondrial disease such as visual disturbance, 169 




Mitochondrial disease patients who underwent cochlear implantation surgery sustained 174 
gains in hearing performance even long after CI surgery. A single patient had poor 175 
postoperative speech perception associated with cognitive problems. Cochlear 176 
implantation for mitochondrial disease patients appears to be a viable treatment option 177 
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FIGURE Legends 243 
Figure 1. Comparison of post-operative speech perception performance test results. 244 
The average scores in the post-operative speech perception performance test for vowels, 245 
consonant-vowel (CV) syllables, and short sentences were compared between 4 246 
mitochondrial disease patients (white boxes, case 1, 2, 4, and 5) and other post-lingually 247 
deafened patients (black boxes) who underwent cochlear implantation. Error bars 248 
indicate standard deviation. No significant difference in any test was detected between 249 
mitochondrial disease patients and other post-lingually deafened patients. Error bars 250 
indicate standard deviation. 251 
 252 
Figure 2. Time course of post-operative speech perception performance in case 1. 253 
The performances for vowels and sentences were well maintained even 8 years after 254 
surgery. 255 
 256 
Figure 3. Time course of post-operative speech perception performance in case 2. 257 
The performances were well maintained 3 years after surgery. 258 
 259 
Figure 4. The outcomes of post-operative speech perception performance test for cases 4 260 
14 
 
and 5. 261 









































































































Summary of patients 




1 F 41 MELAS m.3243A>G 6 years - CI22 
2 F 64 MIDD m.3243A>G 1 years - CI24R 
3 F 41 MELAS N.D. 2 years +++ Combi40+ 
4 M 30 Unclassified m.3243A>G 20 years + Pulsar100 
5 F 36 MELAS m.3243A>G 2 years - CI24RE(CA) 
 
N.D.: not determined; PR: psychomotor regression 
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